Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.

Early RAAS blockade improves renal outcomes in SLE patients with aPLN

06 May 2018

Short- and long-term renal outcomes improve with early renin–angiotensin–aldosterone system (RAAS) blockade with renin–angiotensin system inhibitors (RASI) in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study.

“The renal protective effect of RASI was independent of its antihypertensive and antiproteinuric effects,” the investigators said.

Demographic data, laboratory findings and renal histology by the time of kidney biopsy had no significant difference, but the RASI vs the non-RASI group had higher proteinuria levels (5.2; 2.8–8.8 vs 1.9; 0.6–2.8 g/day, respectively; p=0.005) and higher prevalence of hypertension (75 percent vs 29 percent, respectively; p=0.001).

There was no significant between-group difference in estimated glomerular filtration rate (eGFR), mean arterial pressure and proteinuria level at 12 months after kidney biopsy.

The RASI group had significantly higher improvement ratio of eGFR at 12 months compared with the non-RASI group (26 percent; –5 to 86 percent vs –2 percent; –20 to 20 percent, respectively; p=0.028). The rate of change in eGFR beyond 12 months was comparable between the two groups.

Kidney disease progression occurred in four (23 percent) patients in the non-RASI group and three (8 percent) patients in the RASI group during a mean follow-up of 80 months. Early RAAS blockade significantly reduced the risk of kidney disease progression (hazard ratio, 0.11; 0.02–0.59; p=0.010). Additionally, the two groups had similar proteinuria and hypertension controls.

In this study, the investigators analysed medical data of 57 SLE patients with biopsy-proven aPLN. Early RAAS blockade referred to the administration of RASI within 3 months following kidney biopsy and continued for ≥12 months.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.